524 related articles for article (PubMed ID: 27890854)
1. Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months.
Williet N; Boschetti G; Fovet M; Di Bernado T; Claudez P; Del Tedesco E; Jarlot C; Rinaldi L; Berger A; Phelip JM; Flourie B; Nancey S; Paul S; Roblin X
Clin Gastroenterol Hepatol; 2017 Nov; 15(11):1750-1757.e3. PubMed ID: 27890854
[TBL] [Abstract][Full Text] [Related]
2. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
[TBL] [Abstract][Full Text] [Related]
3. Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases.
Dreesen E; Verstockt B; Bian S; de Bruyn M; Compernolle G; Tops S; Noman M; Van Assche G; Ferrante M; Gils A; Vermeire S
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1937-1946.e8. PubMed ID: 29704680
[TBL] [Abstract][Full Text] [Related]
4. Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases.
Feagan BG; Lasch K; Lissoos T; Cao C; Wojtowicz AM; Khalid JM; Colombel JF
Clin Gastroenterol Hepatol; 2019 Jan; 17(1):130-138.e7. PubMed ID: 29857145
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease.
Amiot A; Grimaud JC; Peyrin-Biroulet L; Filippi J; Pariente B; Roblin X; Buisson A; Stefanescu C; Trang-Poisson C; Altwegg R; Marteau P; Vaysse T; Bourrier A; Nancey S; Laharie D; Allez M; Savoye G; Moreau J; Gagniere C; Vuitton L; Viennot S; Aubourg A; Pelletier AL; Bouguen G; Abitbol V; Bouhnik Y; ;
Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1593-1601.e2. PubMed ID: 26917043
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease.
Christensen B; Gibson PR; Micic D; Colman RJ; Goeppinger SR; Kassim O; Yarur A; Weber CR; Cohen RD; Rubin DT
Clin Gastroenterol Hepatol; 2019 Feb; 17(3):486-493. PubMed ID: 29751166
[TBL] [Abstract][Full Text] [Related]
7. Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study.
Yacoub W; Williet N; Pouillon L; Di-Bernado T; De Carvalho Bittencourt M; Nancey S; Lopez A; Paul S; Zallot C; Roblin X; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2018 Apr; 47(7):906-912. PubMed ID: 29384209
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic drug monitoring of vedolizumab therapy in inflammatory bowel disease.
Steenholdt C; Lorentsen RD; Petersen PN; Widigson ES; Kloft C; Klaasen RA; Brynskov J
J Gastroenterol Hepatol; 2024 Jun; 39(6):1088-1098. PubMed ID: 38380724
[TBL] [Abstract][Full Text] [Related]
9. Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease.
Hanžel J; Sever N; Ferkolj I; Štabuc B; Smrekar N; Kurent T; Koželj M; Novak G; Compernolle G; Tops S; Gils A; Drobne D
United European Gastroenterol J; 2019 Jul; 7(6):741-749. PubMed ID: 31316778
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience.
Kopylov U; Ron Y; Avni-Biron I; Koslowsky B; Waterman M; Daher S; Ungar B; Yanai H; Maharshak N; Ben-Bassat O; Lichtenstein L; Bar-Gil Shitrit A; Israeli E; Schwartz D; Zittan E; Eliakim R; Chowers Y; Ben-Horin S; Dotan I
Inflamm Bowel Dis; 2017 Mar; 23(3):404-408. PubMed ID: 28178003
[TBL] [Abstract][Full Text] [Related]
11. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.
Roblin X; Marotte H; Rinaudo M; Del Tedesco E; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
Clin Gastroenterol Hepatol; 2014 Jan; 12(1):80-84.e2. PubMed ID: 23891927
[TBL] [Abstract][Full Text] [Related]
12. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
[TBL] [Abstract][Full Text] [Related]
13. Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis.
Pouillon L; Rousseau H; Busby-Venner H; De Carvalho Bittencourt M; Choukour M; Gauchotte G; Zallot C; Danese S; Baumann C; Peyrin-Biroulet L
J Crohns Colitis; 2019 Aug; 13(8):970-975. PubMed ID: 30698684
[TBL] [Abstract][Full Text] [Related]
14. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.
Roblin X; Rinaudo M; Del Tedesco E; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
Am J Gastroenterol; 2014 Aug; 109(8):1250-6. PubMed ID: 24913041
[TBL] [Abstract][Full Text] [Related]
15. Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases.
Singh S; Dulai PS; Vande Casteele N; Battat R; Fumery M; Boland BS; Sandborn WJ
Aliment Pharmacol Ther; 2019 Oct; 50(8):848-857. PubMed ID: 31483522
[TBL] [Abstract][Full Text] [Related]
16. Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease.
Löwenberg M; Vermeire S; Mostafavi N; Hoentjen F; Franchimont D; Bossuyt P; Hindryckx P; Rispens T; de Vries A; van der Woude CJ; Berends S; Ambarus CA; Mathot R; Clasquin E; Baert F; D'Haens G
Gastroenterology; 2019 Oct; 157(4):997-1006.e6. PubMed ID: 31175865
[TBL] [Abstract][Full Text] [Related]
17. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J
Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650
[TBL] [Abstract][Full Text] [Related]
18. Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease.
Ungaro RC; Yarur A; Jossen J; Phan BL; Chefitz E; Sehgal P; Kamal K; Bruss A; Beniwal-Patel P; Fox C; Patel A; Bahur B; Jain A; Stein D; Naik S; Dubinsky MC
J Crohns Colitis; 2019 Aug; 13(8):963-969. PubMed ID: 31087100
[TBL] [Abstract][Full Text] [Related]
19. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
Hu A; Kotze PG; Burgevin A; Tan W; Jess A; Li PS; Kroeker K; Halloran B; Panaccione R; Peyrin-Biroulet L; Ma C; Ananthakrishnan AN
Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1366-1376.e2. PubMed ID: 32668338
[TBL] [Abstract][Full Text] [Related]
20. Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis.
Vermeire S; Lukáš M; Magro F; Adsul S; Lindner D; Rosario M; Roth J; Danese S
J Crohns Colitis; 2020 Sep; 14(8):1066-1073. PubMed ID: 32060515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
